Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.75 USD
Change Today 0.00 / 0.00%
Volume 0.0
TBGNF On Other Exchanges
EN Brussels
As of 8:10 PM 09/16/15 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (TBGNF) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/21/14 - $10.25
52 Week Low
08/28/15 - $3.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THROMBOGENICS NV (TBGNF)

Related News

No related news articles were found.

thrombogenics nv (TBGNF) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (TBGNF) Details

ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes ophthalmic and oncology medicines in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat various disorders, such as cancer, age-related macular degeneration, retinopathy, and inflammation; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc. to provide clinical research services for the development of JETREA. The company was founded in 1991 and is headquartered in Leuven, Belgium.

120 Employees
Last Reported Date: 04/4/15
Founded in 1991

thrombogenics nv (TBGNF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €690.0K
Executive Director
Total Annual Compensation: --
Executive Director and Chairman of Audit Comm...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

thrombogenics nv (TBGNF) Key Developments

ThromboGenics Reports Unaudited Consolidated Earnings Results for the First Half Ended June 30, 2015

ThromboGenics reported unaudited consolidated earnings results for the first half ended June 30, 2015. For the period, the company reported income of EUR 5,982,000 compared to EUR 7,149,000 a year ago. Operating loss was EUR 19,789,000 compared to EUR 24,414,000 a year ago. Loss before income tax was EUR 19,178,000 compared to EUR 23,803,000 a year ago. Net loss for the period attributable to equity holders of the company was EUR 19,179,000 or EUR 0.53 per diluted share, compared to EUR 23,849,000 or EUR 0.66 per diluted share a year ago. Net cash used from operating activities was EUR 15,641,000 compared to EUR 23,658,000 a year ago. Acquisition of property, plant and equipment was EUR 211,000 compared to EUR 471,000 a year ago.

ThromboGenics NV, H1 2015 Earnings Call, Aug 26, 2015

ThromboGenics NV, H1 2015 Earnings Call, Aug 26, 2015

ThromboGenics Announces Appointment of Emmanuele Attout as Independent Non-Executive Director

In January, ThromboGenics nominated Emmanuele Attout to be its new Independent non-executive director. Mrs. Attout was appointed during the ThromboGenics Annual Shareholders Meeting of May 5, 2015. She will also join the Audit Committee of the Company. Mrs. Attout has been an audit partner at PricewaterhouseCoopers since 1994. She has been in charge of the audits for a wide range of clients, including in recent years being in charge of the audits of publicly listed pharmaceutical companies and life sciences businesses.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TBGNF:US $4.75 USD 0.00

TBGNF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TBGNF.
View Industry Companies

Industry Analysis


Industry Average

Valuation TBGNF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.1x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at